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The impact of population-based faecal occult blood test screening
on colorectal cancer mortality: a matched cohort study
G Libby*,1, DH Brewster2, PL McClements2, FA Carey3, RJ Black2, J Birrell2, CG Fraser1 and RJC Steele1,4
1Scottish Bowel Screening Research Unit, Kings Cross, Clepington Road, Dundee DD3 8EA, UK; 2National Services Division, NHS National Services
Scotland, 1 South Gyle Crescent, Edinburgh EH12 9EB, UK; 3Department of Pathology, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK;
4Department of Surgery and Molecular Oncology, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
BACKGROUND: Randomised trials show reduced colorectal cancer (CRC) mortality with faecal occult blood testing (FOBT).
This outcome is now examined in a routine, population-based, screening programme.
METHODS: Three biennial rounds of the UK CRC screening pilot were completed in Scotland (2000–2007) before the roll out of a
national programme. All residents (50–69 years) in the three pilot Health Boards were invited for screening. They received a FOBT
test by post to complete at home and return for analysis. Positive tests were followed up with colonoscopy. Controls, selected
from non-pilot Health Boards, were matched by age, gender, and deprivation and assigned the invitation date of matched invitee.
Follow-up was from invitation date to 31 December 2009 or date of death if earlier.
RESULTS: There were 379 655 people in each group (median age 55.6 years, 51.6% male). Participation was 60.6%. There were
961 (0.25%) CRC deaths in invitees, 1056 (0.28%) in controls, rate ratio (RR) 0.90 (95% confidence interval (CI) 0.83–0.99) overall
and 0.73 (95% CI 0.65–0.82) for participants. Non-participants had increased CRC mortality compared with controls, RR 1.21
(95% CI 1.06–1.38).
CONCLUSION: There was a 10% relative reduction in CRC mortality in a routine screening programme, rising to 27% in participants.
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A Cochrane review of the four randomised controlled trials of
screening for colorectal cancer (CRC) using faecal occult blood
testing (FOBT) has shown a reduction in cause-specific mortality,
with an intention to screen analysis, of 16%, rising to 23% when
adjusted for compliance (Towler et al, 1998). On the basis of
these results a demonstration pilot of population-based FOBT was
commissioned in the United Kingdom and the successful
completion has in turn led to a roll out of programmes in all
four UK countries.
Process measures from both the Scottish and English arms of the
UK pilot have been quantified and published (Steele et al, 2009;
Moss et al, 2012). These include cancer detection rate, stage
distribution, and positive predictive value. Disease-specific mor-
tality is the most important outcome measure, and the main aim of
this study was to examine whether the reduction in CRC mortality
seen in the randomised controlled trials could be matched at the
population level in practice.
It is not certain that the reduction in CRC mortality can be
achieved as randomised controlled trials are underpinned by high
levels of motivation within a restricted team and some aspects of
the published trials, for example, diet restriction (Mandel et al,
1993; Kewenter et al, 1994; Kronborg et al, 1996) and high rates
of colonoscopy (Mandel et al, 1993) would not be feasible in
routine population screening. One non-randomised study has been
carried out in France (Faivre et al, 2004) but the screened and
non-screened groups were matched at the level of administrative
area and no account was taken of socio-economic deprivation,
which is a key factor in screening uptake (Steele et al, 2010).
Therefore, a retrospective cohort study was carried out to
compare CRC mortality in the general population routinely invited
for FOBT screening with people not invited but matched at the
individual level for gender, year of birth, and socio-economic status.
MATERIALS AND METHODS
Design of study
The design of the Scottish arm of the UK pilot of FOBT screening
provided the opportunity to compare individuals resident in the
three National Health Service (NHS) boards selected to be involved
in the screening pilot with a matched group drawn from the
remaining NHS boards.
The pilot in Scotland has been described elsewhere (Steele et al,
2009) but in brief individuals aged 50–69 years and living in one of
the three NHS board areas were sent a FOBT kit (hema-screen,
Immunostics, Ocean, NJ, USA) by post to complete at home and
then return to the central laboratory for analysis. This was a
traditional style test consisting of six windows of filter paper
impregnated with guaiac gum. Participants with 5 or 6 positive
windows were offered colonoscopy. Those with 1–4 windows
positive were asked to complete a further guaiac test and
colonoscopy was offered to those with any one window positive.
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There were no dietary restrictions on the initial test. The pilot
consisted of three rounds of biennial screening carried out
between 2000 and 2007 (29 March 2000–31 December 2002, 2
December 2002–30 April 2005, and 6 May 2005–20 July 2007).
Study population
The study population and associated dataset were assembled by
the Information Services Division of NHS National Services
Scotland. All invitees for screening had a community health index
number that is a unique patient identifier for all individuals
registered with a general practitioner in Scotland. A list of the
community health index numbers of those invited in at least one of
the three rounds of screening was compiled and a unique control
person for each invitee, matched for gender, year of birth, and
quintile of deprivation as defined from the Scottish Index of
Multiple Deprivation based on postcode of residence was
identified (www.scotland.gov.uk/topics/Statistics/SIMD). Controls
were selected from NHS boards with background mortality for
CRC comparable to that in the pilot NHS boards. Male controls
were drawn from nine NHS boards and females from five NHS
boards. Controls were not selected from one NHS board because
some of the residents had been invited for screening previously as
part of a UK randomised controlled trial of flexible sigmoidoscopy.
Each control was assigned the date of first screening invitation
of their matched invitee which was used as a proxy screening date.
The invitee and matched control in each pair were then followed
from this date to 31 December 2009 or date of death if earlier.
Using the community health index number, the study population
was record linked to a number of national databases to compile the
data required for the study. Colorectal cancer diagnoses were
obtained from the Scottish Cancer Registry which since 1958 has
collected data on all new cases of cancer arising in the Scottish
population. Hospital admissions for CRC were identified from the
Scottish Morbidity Record database and the date and cause of
death were identified from the National Records of Scotland
database. For this study, only the underlying cause of death was
used and was classified as CRC if coded as ICD10 C18-C20. No
account was taken of potential migration from Scotland and
individuals were deemed to be alive at 31 December 2009 if no date
of death was recorded in the National Records. The invited group
was additionally record linked to the screening database to identify
participation and screening test results.
Exclusions
All individuals in the appropriate age range, resident in the pilot
NHS boards and who had a community health index number were
eligible to be invited for FOBT screening. Before the first round of
screening, however, general practitioners were given the opportu-
nity to identify any patients for whom an invitation for screening
was considered to be inappropriate, for example, patients who
were terminally ill. This was done through the use of prior
notification lists. Their use was discontinued after the first pilot
screening round.
Once the study population had been compiled, matched pairs
were excluded if either person had had a hospital admission for or
a diagnosis of CRC before the screening date or if the control
person had died before the screening date.
Statistical analysis
There were no formal calculations of sample size. All individuals
invited as part of the pilot were included at the start of the study
with the initial aim to find a unique matched control for each.
To compare the results from this study with those from the
randomised controlled trials, an ‘intention to screen’ approach was
used for the main analyses with secondary analyses adjusted for
participation. This was defined as the return of at least one
screening test offered. Demographic differences between partici-
pants and non-participants are regularly seen that could indicate
different underlying risks. Therefore, in addition, the rate of CRC
mortality in those accepting screening was compared with the
controls using the method proposed by Cuzick et al (1997) for
randomised controlled trials that potentially takes account of these
differences.
The primary outcome measure was CRC mortality. Person years
of follow-up in each group were calculated from the screening/
matched date to 31 December 2009 or date of death if earlier.
Cumulative CRC mortality rates with 95% CIs were plotted by year
from the screening/matched date for the invited and control
groups. These were calculated by the Nelson–Aalen method to take
account of length of follow-up (Aalen, 1978).
Overall CRC mortality rates in each group were calculated as the
number of deaths divided by the person years of follow-up. Rate
ratios (RRs) were calculated using the Mantel Haenzel method to
compare these rates in the invited and control groups overall and
by age groups (50–59 and 60–69 years), gender, and participation.
The number needed to be screened was calculated as proposed by
Tabar et al (2004) to account for the rate of screening compliance.
All analyses were carried out with STATA (version 10.0,
StataCorp, College Station, TX, USA).
RESULTS
There were 410 320 individuals invited for screening in at least one
of the three rounds of the pilot. A unique matched control could
not be found for 19 232 of whom 91% were female and 87% were in
the two least deprived quintiles. There were 4824 matched pairs
excluded where a control had died before the matched screening
date or a control or invited person had been diagnosed with or had
a hospital admission for CRC before the screening/matched date.
The number of deaths from all causes over the period of
screening round one (Figure 1) were plotted and appeared to show
an under-representation of deaths in the group invited for
screening. This pattern was not seen in rounds two and three
and might suggest an effect of the prior notification lists sent to
general practitioners. A decision was therefore made to exclude all
individuals who had died before 1 February 2002 and their
matched invited or control person (6609 pairs). This date was
chosen arbitrarily since after this, there was o20% difference
between the numbers of deaths in the two groups. Among the
exclusions were 118 individuals who had died of CRC, 59 in each
group. These exclusions left 379 655 individuals in each of the
invited and control groups (Figure 2).
The demographic characteristics of each group are shown in
Table 1. The unequal distribution of the quintiles of deprivation
reflects the selection of invited and control groups from a
restricted number of NHS boards. In round one, the 50–54 years
age group accounted for 33.1% of the study population but this
rose to 47.4% for the study as a whole due to the majority of those
invited for the first time in rounds two and three being aged 50 or
51 years thus increasing the proportion in the youngest age group.
All cause mortality in the study population was 8.1%. In the invited
group, there were no deaths related to the screening colonoscopy
itself. There were 961 (0.25%) and 1056 (0.28%) deaths from
CRC in the invited and control groups respectively (P¼ 0.03
chi-squared test). A ‘maximum’ result for those in the invited
group was defined over all potential rounds and ranged from ‘not
provided’ (a test kit not being returned) to ‘positive’. Overall 60.6%
of the invited group had returned at least one screening test.
Figure 3 shows the overall cumulative mortality from CRC in
both groups with lower mortality in the invited group appearing
around 4 years after screening. Cumulative mortality rates in the
participants and non-participants compared with their respective
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Pilot NHS boards
Invited   
Non pilot NHS boards
Matched controls 
410–320 
19–232 Not used1
391–088 391–088
4824 Matched pairs excluded2
386–264 386–264
2061 Died
<1 February 2002
4635 Died
<1 February 2002 
6609 Matched pairs excluded3
(2061+4635–4687 common to both groups) 
379–655 379–655
ControlsInvited
1No matched control available.
2Died before screening/matched date or had colorectal cancer
diagnosed before screening/matched date. 
3To account for effect of prior notification lists.
Figure 2 Derivation of study population.
0
25
50
75
100
125
150
175
200
225
250
275
300
325
350
Controls
Invited
Month and year of death
N
um
be
r
De
ce
mb
er-
20
02
No
ve
mb
er-
20
02
Oc
tob
er-
20
02
Se
pte
mb
er-
20
02
Au
gu
st-
20
02
Ju
ly-
20
02
Ju
ne
-20
02
Ma
y-2
00
2
Ap
ril-
20
02
Ma
rch
-20
02
Fe
bru
ary
-20
02
Ja
nu
ary
-20
02
De
ce
mb
er-
20
01
No
ve
mb
er-
20
01
Oc
tob
er-
20
01
Se
pte
mb
er-
20
01
Au
gu
st-
20
01
Ju
ly-
20
01
Ju
ne
-20
01
Ma
y-2
00
1
Ap
ril-
20
01
De
ce
mb
er-
20
00
No
ve
mb
er-
20
00
Oc
tob
er-
20
00
Se
pte
mb
er-
20
00
Au
gu
st-
20
00
Ju
ly-
20
00
Ju
ne
-20
00
Ma
y-2
00
0
Ap
ril-
20
00
Ma
rch
-20
01
Fe
bru
ary
-20
01
Ja
nu
ary
-20
01
Figure 1 Number of all cause deaths in invited for screening and control groups.
Table 1 Demographics of study population
Invited (379 655)
N (%)
Controls (379 655)
N (%)
Females 183 926 (48.4) 183 926 (48.4)
Males 195 729 (51.6) 195 729 (51.6)
SIMD (2009)
1 (Most deprived) 49 598 (13.1) 49 598 (13.1)
2 63 241 (16.7) 63 241 (16.7)
3 83 325 (21.9) 83 325 (21.9)
4 97 985 (25.8) 97 985 (25.8)
5 (Least deprived) 85 506 (22.5) 85 506 (22.5)
Age group at screening (years)
50–54 179 928 (47.4) 179 885 (47.3)
55–59 74 729 (19.7) 74 725 (19.7)
60–64 62 987 (16.6) 62 917 (16.6)
65–69 62 011 (16.3) 62 128 (16.4)
Age at screening
Median years (IQR) 55.6 (51.52–62.34) 55.6 (51.55–62.34)
Status at 31 December 2009
Alive 350 017 (92.19) 348 068 (91.68)
Died: not CRC 28 677 (7.55) 30 531 (8.04)
Died: CRC 961 (0.25) 1056 (0.28)
Cancer site (died CRC)
Colon 536 (55.8) 610 (57.8)
Rectum 425 (44.2) 446 (42.2)
Round first invited
1 280 832 (74.0) —
2 46 444 (12.2) —
3 52 379 (13.8) —
Not participated 149 513 (39.4) —
Participated 230 142 (60.6) —
‘Maximum result’a
Not provided 149 513 (39.4) —
Untestable (spoiled) 1852 (0.5) —
Negative 220 673 (58.1) —
Positive 7617 (2.0) —
Length of follow-up
Median years (IQR) 8.1 (6.11–8.97) 7.9 (6.06–8.97)
Abbreviations: CRC¼ colorectal cancer; IQR¼ interquartile range. aOver all rounds
invited.
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control groups are shown in Figure 4. As seen elsewhere
(Scholefield et al, 2002), CRC mortality rates were lower in the
participants compared with the non-participants and this differ-
ence increased with time following screening.
The overall CRC mortality rate/1000 person years was 0.35 (95%
CI 0.33–0.39) for the invited group and 0.38 (95% CI 0.36–0.41) for
the controls. The RRs showed a 10% relative reduction with
intention to screen RR¼ 0.90 (95% CI 0.83–0.99) and a 27%
relative reduction in participants compared with their matched
controls RR¼ 0.73 (95% CI 0.65–0.82). The Cuzick method showed
a reduction of 17% RR¼ 0.83 (95% CI 0.79–0.87). There was also a
significant reduction in CRC mortality with invitation for screen-
ing for those aged 50–59 years and for males (Table 2).
A sensitivity analysis was carried out to examine the effect on
the overall RR of excluding all those who died before 1 February
2002 and their matched person. The RR remained unchanged
(0.90, 95% CI 0.83–0.99) implying no effect.
The number needed to screen was calculated using data from
round 1 to allow the maximum time of follow-up. There were
155 496 participants in round 1 with 893 CRC deaths in the invited
group and 987 in the controls. The estimated number of CRC
deaths prevented was 94 (987–893). The number of people needed
to be screened for a period of 7 years to prevent one death from
CRC over a follow-up period of 9 years was therefore estimated to
be 1654 (155 496/94). Of 1654 individuals screened over this time
period, 33 (2%) could be expected to have a positive test and 28
(85.5%; Steele et al, 2009) to have a colonoscopy.
DISCUSSION
This study reports the impact of FOBT screening on CRC mortality
in a routine, population-based programme serving a true general
population. The results show that such screening reduces disease-
specific mortality by 10% rising to 27% when adjusted for
participation.
A particular strength of the study was the assessment of CRC
mortality over the same time period in a population being invited
for screening for the first time and a matched cohort with no
history of screening. A limitation, however, was the lack of a
unique control for 19 232 persons invited for screening due to
restricting the selection of matched controls to those from NHS
boards with comparable background mortality. It is not known
what effect if any this would have had on the results but due to the
large size of the study population this group accounted for only 5%
of those invited for screening.
The reduction in mortality was lower than that seen in the meta-
analysis, which was 16% though the individual trial results ranged
from 12 to 19% (Towler et al, 1998). The reason for this is not
clear, but there were two important differences in our study
compared with the randomised controlled trials. First, the study
population was much younger with 47% aged between 50 and 54
years and only 33% aged 60 years or older. This compares to
between 50 and 100% aged 60 years or over in the four trial
populations. Consequently, this study had substantially lower all
cause mortality (8.1%) compared with the trials (16.6–30.5%). In
contrast, CRC as the cause of death accounted for 3.3% of all
deaths in the control group, which was similar to that in the trials
(3.0–3.6%). Colorectal cancer incidence and mortality increase
with age and the lower age range and associated lower risk in the
study population may have reduced the benefit from screening.
The second difference was that the cause of death was defined
only using information from death certificates. In contrast, all the
trials used an expert committee that examined the death certificate
information along with relevant medical records to define the
underlying cause of death. In the Nottingham trial (Hardcastle
et al, 1996), deaths from CRC were classified in two ways,
‘certified’ from death certificate information only and ‘verified’
after additional case note review. The latter approach resulted in
more deaths being defined with a cause of CRC. There was a
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Figure 3 Cumulative mortality from colorectal cancer. Rate and 95% CI
(Nelson–Aalen estimates).
Table 2 Rate ratios of CRC mortality comparing the invited and control
groups
Deaths from CRC
Invited
N (%)
Controls
N (%)
Rate ratio
(95% CI)
All 961 (0.25) 1056 (0.28) 0.90 (0.83–0.99)
Person years 2 777 086 2 767 873
Participants 494 (0.21) 664 (0.29) 0.73 (0.65–0.82)
Participants–Cuzick method 0.83 (0.79–0.87)
Non-participants 467 (0.31) 392 (0.26) 1.21 (1.06–1.38)
Age group at screening date (years)
50–59 345 (0.14) 401 (0.16) 0.86 (0.74–0.99)
60–69 616 (0.49) 655 (0.52) 0.94 (0.84–1.05)
Females 375 (0.20) 397 (0.22) 0.94 (0.82–1.09)
Males 586 (0.29) 659 (0.34) 0.89 (0.79–0.99)
Abbreviation: CRC¼ colorectal cancer.
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Figure 4 Cumulative mortality from colorectal cancer by participation
(Nelson–Aalen estimates).
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statistically significant reduction in CRC mortality of 15% only
in the larger ‘verified’ group. The ‘certified’ group showed a
nonsignificant reduction of 12%.
These two differences may have contributed to the lower
reduction in mortality seen in this study compared with the meta-
analysis (Towler et al, 1998). In addition, colonoscopy was offered
directly to those with 5 or 6 FOBT windows positive (strong
positive) but not those with 1–4 windows positive (weak positive)
until they had another positive FOBT result. This approach was
based on the algorithm used in the Nottingham trial and
was designed, considering the available colonoscopy resource, to
achieve a positivity rate of 2%. It has been suggested that this is too
conservative an approach resulting in a diminution of the benefit
of screening compared with the benefit if all those with a positive
test result were referred for colonoscopy. Another trial in the
United States gained an increased positivity rate through rehydra-
tion of the FOBT (Mandel et al, 1993). This resulted in higher
colonoscopy rates and showed an increased reduction in mortality
of 19% but with a lower positive predictive value because of the
increased number of false positive test results. Offering colono-
scopy directly to weak positives, therefore, may have led to a
greater reduction in mortality, but a recent study has shown that
where colonoscopy is undertaken following a weak positive test
result, the positive predictive value for cancer is 8.8% compared
with 26% for those with a strong positive test (Lee et al, 2011).
It is encouraging, however, that a significant reduction in CRC
mortality was achieved despite the limitations that are important
factors in routine, real-world screening programmes in contrast to
studies undertaken with the advantages of clinical trial support.
It was found that all cause mortality was slightly greater in the
control group than in the invited group raising the possibility that
the reduction in CRC mortality could have been partly due to
differences in overall mortality. However, the statistically sig-
nificant differences between the groups were confined to non-
cancer causes of death with no differences between the groups for
any cancer other than CRC (data not shown). Thus, it is unlikely
that the reduction in CRC mortality could be due to background
differences in overall mortality.
Previously published studies of routine screening programmes
have shown that screening with FOBT leads to an increased
detection of CRC at early stages of disease (Steele et al, 2009; Moss
et al, 2012). This study shows that these outcomes translate into
a reduction in cause-specific mortality justifying the introduction
of routine population-based screening. It seems likely that a
greater impact of screening on CRC mortality would be realised
with increased participation.
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